Clinical Trial Update: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity [Phase 3]

View source ↗

Summary

Phase 3 multicenter, double-blind, randomized, placebo-controlled trial evaluating GSK1358820 (botulinum toxin type A) for post-stroke upper limb spasticity in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-stroke Upper Limb Spasticity
• Stroke

Drugs mentioned

• GSK1358820

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cerebrovascular Accident | Phase 3 | Status: COMPLETED | Results posted: 2012-05-17